Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants

Vaccine

Volumn 17, Issue 20-21, 1999, Pages 2715-2725

  Clements Mann, Mary Lou ^a,b   Makhene, Mamodikoe K ^a   Mrukowicz, Jacek ^c   Wright, Peter F ^c   Hoshino, Yasutaka ^d   Midthun, Karen ^a,b   Sperber, Ellen ^a   Karron, Ruth ^a,b   Kapikian, Albert Z ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Diarrheal vaccines; Human bovine reassortant rotavirus vaccines; Live attenuated virus vaccines; Pediatric vaccines; Rotavirus vaccines

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIVE VACCINE; NEUTRALIZING ANTIBODY; ROTAVIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RNA VIRUS INFECTION; ROTAVIRUS; SEROTYPE; VIRUS ATTENUATION; VIRUS INFECTIVITY; VIRUS TYPING;

EID: 0033522950     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00497-6     Document Type: Article

References (38)

1. Kapikian AZ, Chanock RM. Rotaviruses. In: Fields BN, Knipe DM, Howley PM et al., editors. Fields Virology, vol. 2. 3rd ed. Philadelphia: Lippincott-Raven Publishers, 1995. p. 1657-1708.
2. Glass R.I., Kilgore P.E., Holman R.C., et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis. 174:1996;S5-11.
3. Bern C., Glass R.I. Impact of diarrheal diseases. Kapikian A.Z., Viral infections of the gastrointestinal tract. 2nd ed. 1994;1-26 Marcel Dekker, Inc, New York.
4. Midthun K., Greenberg H.B., Hoshino Y., Kapikian A.Z., Wyatt R.G., Chanock R.M. Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol. 53:1985;949-954.
5. Midthun K., Hoshino Y., Kapikian A.Z., Chanock R.M. Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4. J Clin Microbiol. 24:1986;822-826.
6. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA. for U.S Rotavirus Vaccine Efficacy Group. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995;273:1191-6.
7. Pérez-Schael I., Gutiñas M.J., Pérez M., et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med. 337:1997;1181-1187.
8. Rennels M.B., Glass R.I., Dennehy P.H., et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines: report of the National Multicenter trial. Ped. 97:1996;7-13.
9. Joensuu J., Koskenniemi E., Pang X.-L., Vesikari T. Randomised placebo-controlled trial in rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet. 350:1997;1205-1209.
10. Santosham M., Moulton L.H., Reid R., et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr. 131:1997;632-638.
11. Flores J., Perez-Schael I., Blanco M., et al. Reactions to and antigenicity of two human-rhesus rotavirus reassortant vaccine candidates of serotypes 1 and 2 in Venezuelan infants. J Clin Microbiol. 27:1989;512-518.
12. Flores J., Perez-Schael I., Blanco M., et al. Comparison of reactogenicity and antigenicity of M37 rotavirus vaccine and rhesus-rotavirus-based quadrivalent vaccine. Lancet. 336:1990;330-334.
13. Perez-Schael I., Blanco M., Vilar M., et al. Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants. J Clin Microbiol. 28:1990;553-558.
14. Vesikari T., Ruuska T., Green K.Y., Flores J., Kapikian A.Z. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity. Pediatr Infect Dis J. 11:1992;35-42.
15. Vesikari T., Varis T., Green K., Flores J., Kapikian A.Z. Immunogenicity and safety of rhesus-human rotavirus reassortant vaccines with serotype 1 or 2 VP7 specificity. Vaccine. 9:1991;334-339.
16. Flores J., Perez-Schael I., Blanco M., et al. Reactogenicity and immunogenicity of a high-titer rhesus rotavirus-based quadrivalent rotavirus vaccine. J Clin Microbiol. 31:1993;2439-2445.
17. Bernstein D.I., Smith V.E., Sander D.S., Pax K.A., Schiff G.M., Ward R.L. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis. 162:1990;1055-1062.
18. Clark H.F., Furukawa T., Bell L.M., Offit P.A., Perrella P.A., Plotkin S.A. Immune response of infants and children to low-passage bovine rotavirus (strain WC3). Am J Dis Child. 140:1986;350-356.
19. Gouvea V., Santos N., Timenetsky M. do C. Identification of bovine and porcine rotavirus G type by PCR. J Clin Microbiol. 32:1994;1333-1337.
20. Bridger J.C., Woode G.N. Neonatal calf diarrhea: identification of a reovirus-like (rotavirus) agent in faeces by immunofluoresence and immune electron microscopy. Br Vet J. 131:1975;528-535.
21. Wyatt R.G., Kapikian A.Z., Hoshino Y., et al. Development of rotavirus vaccines: control and eradication of infectious diseases: an International Symposium. PAHO Copublication Series. No. 1:1995;17-28.
22. Kapikian A.Z., Hoshino Y., Flores J., et al. Alternate approaches to the development of a rotavirus vaccine. Holmgren J., Lindberg A., Molby R., Development of vaccines and drugs against diarrhea, 11th Nobel Conference, Stockholm, Sweden 1985. 1986;192-214 Studentlitteratur, Lund.
23. Halsey N.A., Anderson E.L., Sears S.D., et al. Human-rhesus reassortant rotavirus vaccines: safety and immunogenicity in adults, infants and children. J Infect Dis. 158:1988;1261-1267.
24. Midthun K., Pang L., Flores J., Kapikian A.Z. Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme linked immunosorbent assays, plaque reduction neutralization assay and complement fixation in detecting seroresponses to rotavirus vaccine candidates. J Clin Microbiol. 27:1989;2799-2804.
25. Hoshino Y., Wyatt R.G., Flores J., Midthun K., Kapikian A.Z. Serotypic characterization of rotaviruses derived from asymptomatic human neonatal infection. J Clin Microbiol. 21:1985;425-430.
26. Gouvea V., Glass R.I., Woods P., et al. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens. J Clin Microbiol. 28:1990;276-282.
27. Gouvea V., Santos N., Timenetsky M. do C. VP4 typing of bovine and porcine group A rotaviruses by PCR. J Clin Microbiol. 32:1994;1333-1337.
28. Christy C., Offitt P., Clark H.F., Treanor J. Evaluation of a bovine human rotavirus reassortant vaccine in infants. J Infect Dis. 168:1993;1598-1599.
29. Clark H.F., Borian F.E., Modesto K., Plotkin S.A. Serotype 1 reassortant of bovine rotavirus WC3, strain WI79-9 induces a polytypic antibody response in infants. Vaccine. 8:1990;327-332.
30. Treanor J.J., Clark H.F., Pichichero M., et al. Evaluation of protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. Pediatr Infect Dis J. 14:1995;301-307.
31. Clark H.F. Response of adult human volunteers to oral administration of bovine and bovine-human reassortant rotaviruses. Vaccine. 4:1986;25-31.
32. Vesikari T., Joensuu J. Review of rotavirus vaccine trials in Finland. J. Infect. Dis. 174:(Suppl):1996;S81-87.
33. Taniguchi K., Urasawa T., Kobayashi N., et al. Antibody response to serotype-specific and cross-reactive neutralization epitopes on VP4 and VP7 after rotavirus infection or vaccination. J Clin Microbiol. 29:1991;483-487.
34. Simasathien S., Migasena S., Samakoses R., et al. Vaccination of Thai infants with rhesus-human reassortant tetravalent oral rotavirus vaccine. Pediatr Infect Dis J. 13:1994;590-596.
35. Madore H.P., Christy C., Pichichero M., et al. Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. J Infect Dis. 166:1992;235-243.
36. Clark H.F., Borian F.F., Plotkin S.A. Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3. J Infect Dis. 161:1990;1099-1104.
37. Ward R.L., McNeal M.M., Sander D.S., Greenberg H.B., Bernstein D.I. Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children. J Virol. 67:1993;464-468.
38. Green K.Y., Taniguchi K., Mackow E.R., Kapikian A.Z. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. J Infect Dis. 161:1990;667-679.